Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Michael Untch"'
Autor:
Marion T. van Mackelenbergh, Fenja Seither, Volker Möbus, Joyce O'Shaughnessy, Miguel Martin, Heikki Joensuu, Michael Untch, Ulrike Nitz, Guenther G. Steger, Juan J. Miralles, Carlos H. Barrios, Masakazu Toi, Harry D. Bear, Hyman Muss, Toralf Reimer, Valentina Nekljudova, Sibylle Loibl
Publikováno v:
European journal of cancer (Oxford, England : 1990). 166
Despite the large number of patients with early breast cancer (EBC) who have been treated with capecitabine in randomised trials, no individual patient data meta-analysis has been conducted. The primary objective was to examine the effect of capecita
Autor:
Esther Pohl-Rescigno, Peter Klare, Gbg, Kristina Lübbe, Michael Untch, Kerstin Rhiem, Carsten Denkert, Jens Huober, Hans Tesch, Andreas Schneeweiss, Sibylle Loibl, Christian Jackisch, Karin Kast, Rita K. Schmutzler, Christine Solbach, Theresa Link, Valentina Nekljudova, L Michel, Peter A. Fasching, Claus Hanusch, Eric Hahnen, Volker Möbus, Ago-B, Jens-Uwe Blohmer
Publikováno v:
European journal of cancer (Oxford, England : 1990). 160
Background GeparOcto demonstrated that pathological complete response (pCR) of intense dose-dense epirubicin, paclitaxel and cyclophosphamide (iddEPC) was comparable to weekly paclitaxel/non-pegylated liposomal doxorubicin (plus carboplatin (PM(Cb) i
Autor:
Volkmar Müller, Alexander Hein, Andreas D. Hartkopf, Peter A. Fasching, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Matthias W. Beckmann, Andreas Schneeweiss, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Julia Meyer, Lena A. Wurmthaler, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Laura L. Michel
Publikováno v:
European journal of cancer (Oxford, England : 1990). 172
Patients with de novo metastatic breast cancer (dnMBC) may have different clinical and pathological characteristics. In studies concerned with first-line metastatic patients, the proportion of these patients without secondary resistance mechanisms ma
Autor:
Marion van Mackelenbergh, Peter A. Fasching, Andreas Schneeweiss, Michael Untch, Elmar Stickeler, Valentina Nekljudova, Frederik Marmé, Sabine Seiler, Jenny Furlanetto, Eva-Maria Grischke, Christian Schem, Carsten Denkert, Volkmar Müller, M Bassy, Thomas Karn, Sabine Schmatloch, Sibylle Loibl, C. Thode, D. Strik
Publikováno v:
European journal of cancer (Oxford, England : 1990). 152
Young women receiving chemotherapy for early breast cancer (EBC) have a high probability for ovarian failure, defined by chemotherapy-induced amenorrhea (CIA) as a surrogate. CIA is insufficiently reliable and reproducible. We analysed chemotherapy-i
Autor:
Garrick Kassab, José Baselga, Alvaro Moreno-Aspitia, Otto Metzger Filho, Richard D. Gelber, David W. Hillman, Kamal S Saini, Christine Campbell, Ann E. McCullough, Larissa A. Korde, Antonio C. Wolff, Masakazu Toi, Kathleen I. Pritchard, Miguel Izquierdo, Zeba Aziz, Daniela Dornelles Rosa, Frances M. Boyle, Ian E. Smith, Celine Schurmans, Georgia Demetriou, István Láng, Michael Untch, Binghe Xu, Zhimin Shao, Eileen Holmes, Evandro de Azambuja, Carlos Barrios, Eleanor McFadden, Martin Andersson, Martine Piccart-Gebhart, Debora Fumagalli, Sung Hoon Sim, Robin McConnell, Christian Jackisch, Ajay O. Mehta, Sarra El-Abed, Vicki Paterson, Emma Paterson, Florentine Hilbers, Michael S. Ewer, Vasiliki Balta, Sebastien Guillaume
Publikováno v:
Eur J Cancer
Aim To present the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial. Patients and methods 8381 patients with stage I-III HER2 positive breast cancer randomised to chemotherapy plus 1-year of trastuzumab (T), oral lapatinib (L
Autor:
Christian Jackisch, Christophe Lecocq, Serena Di Cosimo, Frances M. Boyle, José Baselga, Michael Untch, Ian E. Smith, Eileen Holmes, Hans Wildiers, Debora Fumagalli, Martine Piccart-Gebhart, Jens Huober, Hryhoriy Adamchuk, Lorena de la Peña, Richard D. Gelber, Tamas Hickish, John Hackman, Binghe Xu, Evandro de Azambuja, Eva Ciruelos, Juan Carlos Toral Pena, Severine Sarp, Lokanatha Dasappa, István Láng, Christelle Jouannaud
Publikováno v:
European journal of cancer (Oxford, England : 1990). 118
BACKGROUND: Lapatinib (L) plus trastuzumab (T) with weekly paclitaxel significantly increased the pathologic complete response (pCR) rate compared with the anti-human epidermal growth factor receptor 2 (HER2) agent alone plus paclitaxel. The event-fr
Autor:
Jörn Hilfrich, Jens Huober, Holger Eidtmann, Stefan Paepke, Bianca Lederer, Serban-Dan Costa, Sibylle Loibl, Michael Untch, Frederik Marmé, Christian Jackisch, Claus Hanusch, Jens-Uwe Blohmer, Bernd Gerber, Andreas Schneeweiss, Carsten Denkert, Gunter von Minckwitz, Sherko Kümmel
Publikováno v:
European journal of cancer (Oxford, England : 1990). 53
Background Pathologic complete response after neoadjuvant chemotherapy (NACT) correlates with overall survival (OS) in primary breast cancer. A recently described staging system based on pre-treatment clinical stage (CS), final pathological stage (PS
Autor:
Valentina Nekljudova, Hans Tesch, Gunter von Minckwitz, Jörn Hilfrich, K. Schwedler, Serban-Dan Costa, Christine Mau, Peter A. Fasching, Jens-Uwe Blohmer, Petra Krabisch, Cornelia Höß, K Kittel, Jens Huober, Sherko Kümmel, Christian Jackisch, Holger Eidtmann, Michael Untch, F Khandan, Claus Hanusch, Bernd Gerber, Mahdi Rezai, Sibylle Loibl
Publikováno v:
European journal of cancer (Oxford, England : 1990). 49(10)
Background We tested the oral mammalian target of rapamycin (mTOR) inhibitor everolimus in addition to paclitaxel in patients with HER2-negative tumours not responding to initial neoadjuvant cytotoxic and anti-angiogenic treatment. Methods Patients w